Industry
Biotechnology
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Loading...
Open
0.47
Mkt cap
20M
Volume
180K
High
0.49
P/E Ratio
-0.51
52-wk high
5.95
Low
0.47
Div yield
N/A
52-wk low
0.41
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 8:05 pm
Portfolio Pulse from Avi Kapoor
March 14, 2024 | 6:47 pm
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 3:08 pm
Portfolio Pulse from Avi Kapoor
March 14, 2024 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 1:29 pm
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.